The anxiolytic effects of flesinoxan, a 5-HT1A receptor agonist, are not related to its neuroendocrine effects

Eur J Pharmacol. 1995 Jul 4;280(2):185-93. doi: 10.1016/0014-2999(95)00209-4.

Abstract

The effects of flesinoxan, a selective 5-HT1A receptor agonist, were studied under basal non-stress conditions and in the shock-probe burying paradigm. Flesinoxan (1 and 3 mg/kg s.c.) significantly reduced burying and freezing behaviour, indicating clear anxiolytic properties. Under non-stress conditions, injection of 3 mg/kg flesinoxan significantly enhanced plasma corticosterone and glucose levels, whereas prolactin secretion was significantly enhanced after both 1 mg/kg and 3 mg/kg flesinoxan. Flesinoxan (1 and 3 mg/kg) did not suppress shock-probe stress-induced rises in plasma corticosterone and glucose levels. The enhanced plasma prolactin levels induced by flesinoxan were not further affected by shock-probe exposure. Our data show that the anxiolytic effects of flesinoxan in the shock-probe burying paradigm are not related to increases in plasma corticosterone and glucose levels.

MeSH terms

  • Animals
  • Anti-Anxiety Agents / pharmacology*
  • Behavior, Animal / drug effects
  • Blood Glucose / metabolism
  • Corticosterone / blood
  • Dose-Response Relationship, Drug
  • Electroshock
  • Male
  • Neurosecretory Systems / drug effects*
  • Piperazines / pharmacology*
  • Prolactin / blood
  • Rats
  • Rats, Wistar
  • Serotonin Receptor Agonists / pharmacology*

Substances

  • Anti-Anxiety Agents
  • Blood Glucose
  • Piperazines
  • Serotonin Receptor Agonists
  • flesinoxan
  • Prolactin
  • Corticosterone